In contrast to these studies, which identified lesions or gene expression states potentially sensitizing AML cells to atRA, the AML associated transcription factor fusion protein AML1-ETO was reported to confer atRA resistance [94]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.